Generic drug of the therapeutic class: Ophthalmology
active ingredients: Methipranolol
Bottle of 3 ml
- Intraocular hypertonia.
- Chronic open angle glaucoma.
Dosage BETANOL 0.1% Eye drops 3 ml bottle
IN EYE INSTILLATION.
The dosage is one drop BETOLOL 0.1 PERCENT, to be instilled in the sick eye, twice a day.
- It is recommended to start treatment with BETANOL 0.1 PERCENT eye drops.
- In case of insufficient efficiency, switch to more concentrated eye drops (0.3% then 0.6%).
In a number of cases, the daily administration of a single drop of metipranolol in eye drops may be sufficient, especially when the intraocular pressure has been maintained at satisfactory levels.
- The ophthalmologist may, if he deems it necessary, associate metipranolol with eye drops with one or more other antiglaucomatous treatments (locally and / or generally).
- However, the combination of two beta-blocking eye drops is not recommended (see precautions for use).
- The other eye drops should be administered at least 15 minutes before BETANOL.
However, the normalization of ocular pressure by the eye drops sometimes requires a few weeks, so the evaluation of the treatment should include a measurement of intraocular pressure after a treatment period of about 4 weeks.
Substitution of previous treatment:
- When the eye drops BETANOL must take over another antiglaucoma eye drops, this eye drops should be stopped at the end of a full day of treatment, and BETANOL should be administered the next day at a rate of 0, 1% in the sick eye, twice a day.
- In case of insufficient efficacy, use a more concentrated eye drops (0.3% then 0.6%).
- If BETANOL eye drops are to be substituted for several antiglaucomatous agents, deletions should be made for only one drug at a time.
- In the case of substitution of eye drops with BETANOL eye drops, an examination of the refraction may be necessary when the effects of miotics have disappeared.
- The medical prescription will be accompanied by the control of intraocular pressure, especially during the initiation of treatment.
The contraindications to systemically administered beta-blockers should be borne in mind, although the systemic effects of beta-blockers are only exceptionally observed after eye instillation .
- hypersensitivity to any of the components of the drug,
- asthma or chronic obstructive pulmonary disease,
- heart failure not controlled by treatment,
- cardiogenic shock,
- non-paired second and third degree atrioventricular blocks, Prinzmetal's angina,
- sinus disease (including sinoatrial block),
- bradycardia (<45-50 contractions per minute),
- Raynaud's disease and circulatory disorders,
- untreated pheochromocytoma,
- association with floctafenine (see interactions),
- association with sultopride (see interactions).
NOT RECOMMENDED :
- This drug should not usually be associated with amiodarone (see interactions).
- The combination of two beta-blocking eye drops is not recommended.
- Use in children: this eye drops has not been the subject of clinical studies in premature infants, newborns and children. The use of this eye drops is not recommended in these patients.
- Breast-feeding: Beta-blockers are excreted in the milk. The risk of hypoglycaemia and bradycardia has not been evaluated: therefore, as a precaution, breastfeeding is not recommended during the course of treatment.
Betanol side effects
As with all beta-blocker eye drops, it can be observed:
- a decrease of the lacrimal secretion (dry eye);
- symptoms of eye irritation: slight burning or stinging sensation at the beginning of treatment;
conjunctival hyperemia, conjunctivitis, blepharitis, keratitis, corneal hypoesthesia;
- visual disturbances including changes in refraction (sometimes due to cessation of treatment by miotics), diplopia, ptosis;
- choroidal detachment after surgical treatment of glaucoma (see warnings and precautions for use).
The side effects of systemically administered beta-blockers should be borne in mind, although they are only exceptionally observed after ocular instillation.
ON THE CLINICAL PLAN:
- The most frequently reported:
. cooling of the ends,
. bradycardia, severe if any,
. insomnia, nightmares or depression,
. digestive disorders (gastralgia, nausea, vomiting, diarrhea).
- Much more rarely:
. slowing of atrioventricular conduction or intensification of an existing atrioventricular block,
. heart failure,
. blood pressure drop,
. Raynaud's syndrome,
. worsening of existing intermittent claudication,
. skin manifestations including urticaria, angioedema (angioedema), rash, psoriasiform rash (see warnings and precautions for use).
ON THE BIOLOGICAL PLAN:
In rare cases, it has been possible to observe the appearance of antinuclear antibodies which only exceptionally accompany clinical manifestations such as lupus syndrome and cede at the end of treatment.